Profile data is unavailable for this security.
About the company
Kringle Pharma Inc is a Japan-based company mainly engaged in the development of pharmaceuticals. The Company is involved in the research and development of therapeutic agents for intractable diseases using hepatocyte growth factor (HGF) protein. HGF has versatile bioactivity that is responsible for tissue or organ regeneration and protection such as cell proliferation promotion, cell motility promotion, anti-apoptosis, morphogenesis induction, and angiogenesis. HGF has a therapeutic effect on chronic fibrotic diseases such as liver cirrhosis, chronic renal failure, pulmonary fibrosis and cardiomyopathy. HGFs target diseases are Atrophic lateral sclerosis (ALS), Acute renal impairment, Vocal scar and others. The Company is involved in the general new drug development processes such as basic research, non-clinical trials and manufacturing, clinical trials, approval application and authorization, marketing and expansion of indications.
- Revenue in JPY (TTM)80.04m
- Net income in JPY-756.45m
- Incorporated2001
- Employees13.00
- LocationKringle Pharma Inc207Saito Bio Incubator, 7-7-15, SaitoasagiIBARAKI-SHI 567-0085JapanJPN
- Phone+81 726418739
- Fax+81 726418730
- Websitehttps://www.kringle-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ribomic Inc | 2.11m | -949.28m | 3.38bn | 24.00 | -- | 1.03 | -- | 1,603.44 | -25.76 | -25.76 | 0.057 | 80.86 | 0.0006 | -- | 0.0677 | 87,791.66 | -25.76 | -30.52 | -26.68 | -31.71 | -- | -- | -45,053.58 | -1,777.84 | 30.87 | -- | 0.00 | -- | -100.00 | -- | 38.04 | -- | 4.42 | -- |
| Human Metabolome Technologies Inc | 1.38bn | 246.02m | 3.58bn | 58.00 | 14.52 | 1.97 | 10.24 | 2.58 | 41.59 | 41.59 | 234.08 | 306.43 | 0.6291 | 8.87 | 7.76 | 23,872,380.00 | 11.18 | 8.49 | 14.00 | 10.80 | 65.13 | 69.25 | 17.77 | 13.21 | 3.73 | 33.22 | 0.1088 | 18.31 | 3.57 | -- | -14.88 | -- | -- | -- |
| Cyfuse Biomedical KK | 57.69m | -718.81m | 3.94bn | 21.00 | -- | 1.44 | -- | 68.23 | -89.81 | -89.81 | 7.24 | 335.21 | 0.0147 | 0.5261 | 40.19 | 2,747,238.00 | -18.36 | -- | -21.62 | -- | 55.40 | -- | -1,245.95 | -- | 5.52 | -91.45 | 0.2268 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
| D.Western Therapeutics Institute Inc | 464.18m | -1.09bn | 3.95bn | 21.00 | -- | 4.03 | -- | 8.51 | -33.74 | -33.74 | 14.43 | 25.80 | 0.19 | 0.3314 | 4.10 | 22,103,620.00 | -44.77 | -13.06 | -47.81 | -14.36 | 91.27 | 94.29 | -235.62 | -72.51 | 18.24 | -- | 0.5644 | -- | -4.40 | 7.90 | -89.07 | -- | 7.08 | -- |
| BrightPath Biotherapeutics Co Ltd | 84.00k | -1.15bn | 4.61bn | 24.00 | -- | 3.67 | -- | 54,830.12 | -16.73 | -16.73 | 0.0012 | 14.73 | 0.00006 | -- | 2.80 | 3,500.00 | -80.63 | -51.56 | -97.29 | -54.32 | 75.00 | 68.63 | -1,372,495.00 | -22,321.82 | -- | -- | 0.2085 | -- | -98.64 | -78.47 | 21.37 | -- | -46.55 | -- |
| FunPep Co Ltd | 530.00k | -727.29m | 4.70bn | 15.00 | -- | 1.76 | -- | 8,866.56 | -29.40 | -29.40 | 0.0215 | 82.55 | 0.0002 | -- | -- | 35,333.33 | -26.27 | -27.10 | -29.12 | -28.75 | -- | -- | -137,223.40 | -815.82 | 5.06 | -1,004.01 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
| DNA Chip Research Inc | 766.32m | -118.13m | 4.75bn | 37.00 | -- | 6.77 | -- | 6.20 | -18.29 | -18.29 | 116.80 | 103.64 | 0.9159 | 8.50 | 7.86 | 20,711,350.00 | -14.12 | -23.49 | -17.74 | -26.70 | 38.52 | 14.28 | -15.41 | -54.10 | 2.78 | -641.51 | 0.00 | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
| Kidswell Bio Corp | 3.60bn | -883.62m | 4.80bn | 42.00 | -- | 5.60 | -- | 1.33 | -22.78 | -22.78 | 92.26 | 21.08 | 0.9182 | 2.73 | 6.63 | 85,697,070.00 | -22.54 | -57.41 | -35.96 | -81.13 | 36.17 | 55.20 | -24.55 | -123.52 | 1.64 | -17.95 | 0.7132 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
| Kringle Pharma Inc | 80.04m | -756.45m | 5.86bn | 13.00 | -- | 2.78 | -- | 73.18 | -118.21 | -118.21 | 12.71 | 309.55 | 0.0298 | -- | 1.15 | -- | -28.14 | -19.17 | -30.03 | -20.40 | -- | -- | -945.12 | -181.86 | 19.20 | -- | -- | -- | 15.58 | -- | 11.44 | -- | -- | -- |
| Veritas In Silico Inc | 246.24m | -148.31m | 5.87bn | 15.00 | -- | 2.55 | -- | 23.84 | -23.92 | -23.92 | 38.93 | 354.61 | 0.1227 | -- | -- | 16,415,930.00 | -7.39 | -- | -7.65 | -- | -- | -- | -60.23 | -- | 67.03 | -- | -- | -- | 101.54 | -- | 123.38 | -- | -- | -- |
| Carna Biosciences, Inc. | 1.40bn | -1.51bn | 5.94bn | 67.00 | -- | 2.11 | -- | 4.24 | -85.98 | -85.98 | 80.34 | 147.09 | 0.391 | 1.19 | 13.59 | 20,922,580.00 | -42.15 | -14.45 | -45.45 | -16.95 | 87.53 | 90.59 | -107.80 | -35.42 | 11.11 | -- | 0.0215 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
| Noile-Immune Biotech Inc | 8.12m | -1.07bn | 7.27bn | 28.00 | -- | 1.48 | -- | 896.12 | -24.64 | -24.64 | 0.1875 | 113.23 | 0.0015 | 0.0229 | 0.0283 | 289,928.60 | -19.15 | -- | -19.61 | -- | 95.58 | -- | -13,139.53 | -- | 79.60 | -- | -- | -- | -49.37 | -- | -192.28 | -- | -- | -- |
| OncoTherapy Science, Inc. | 478.75m | -1.12bn | 8.15bn | 54.00 | -- | 8.15 | -- | 17.02 | -4.86 | -4.86 | 2.04 | 3.68 | 0.3526 | 4.34 | 9.77 | 8,865,722.00 | -82.71 | -55.67 | -106.53 | -63.82 | -32.12 | -1.49 | -234.61 | -247.47 | 3.11 | -- | 0.0731 | -- | -46.24 | 16.81 | -15.15 | -- | -48.33 | -- |
| TMS Co Ltd | 0.00 | -1.10bn | 8.27bn | 14.00 | -- | 2.77 | -- | -- | -28.37 | -28.37 | 0.00 | 74.10 | 0.00 | -- | -- | 0.00 | -33.57 | -- | -34.42 | -- | -- | -- | -- | -- | 31.13 | -- | 0.00 | -- | -- | -- | -11.51 | -- | -- | -- |
| Linical Co Ltd | 11.67bn | -121.16m | 8.54bn | 662.00 | -- | 1.06 | 20.77 | 0.7314 | -5.36 | -5.36 | 516.67 | 326.90 | 0.6575 | -- | 3.74 | 17,628,030.00 | -0.6826 | 4.01 | -1.18 | 6.33 | 26.63 | 30.99 | -1.04 | 5.48 | -- | 2.65 | 0.2588 | 50.81 | -1.67 | 1.70 | -66.32 | -9.86 | -10.18 | 4.56 |
Data as of Nov 22 2024. Currency figures normalised to Kringle Pharma Inc's reporting currency: Japanese Yen JPY
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Daiwa Asset Management Co. Ltd.as of 29 Aug 2023 | 0.00 | 0.00% |
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
